Dow Jones received a payment from EQS/DGAP to publish this press release.
Sartorius Stedim Biotech SA: Change of the liquidity contract
20-Apr-2018 / 07:00 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Sartorius Stedim Biotech S.A.: Change of the liquidity contract
Aubagne, France | April 20, 2018
Review of the end of the liquidity contract concluded with GILBERT DUPONT
SARTORIUS STEDIM BIOTECH and GILBERT DUPONT terminated the liquidity
contract concluded on November 3, 2017. This termination took effect on
April 19, 2018, after market close.
As of April 19, 2018, the following assets appeared on the liquidity
account:
- Number of shares: 432
- Liquidity account cash balance: EUR 613,104.61
Conclusion of a new liquidity contract with GILBERT DUPONT
Sartorius Stedim Biotech and Gilbert Dupont signed on April 17, 2018, a new
liquidity contract in compliance with the AMAFI charter which will be
effective on April 20 before market opening.
For the implementation of the new contract, the following assets appear on
the liquidity account:
- Liquidity account cash balance: EUR 650,000
It is reiterated that, at the yearly review of 31 December 2017, the
following resources were in the
liquidity account:
- Number of shares: 2,178
- Liquidity account cash balance: EUR 475,474.10
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international supplier of products and
services that enable the biopharmaceutical industry to develop and
manufacture drugs safely and efficiently. As a total solutions provider,
Sartorius Stedim Biotech offers a portfolio covering nearly all steps of
biopharmaceutical manufacture. The company focuses on single-use
technologies and value-added services to meet the rapidly changing
technology requirements of the industry it serves. Headquartered in Aubagne,
France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext
Paris. With its own manufacturing and R&D sites in Europe, North America and
Asia and an international network of sales companies, Sartorius Stedim
Biotech has a global reach. In 2017, the company employed approx. 5,100
people, and earned sales revenue of 1,081.0 million euros.
Contact
Petra Kirchhoff, Vice President of Corporate Communications
Phone: +49(0)551.308.1686 | petra.kirchhoff@sartorius.com
Regulatory filing PDF file
Document title: CHANGE OF THE LIQUIDITY CONTRACT
Document: http://n.eqs.com/c/fncls.ssp?u=WWKRTGMKXI [1]
Language: English
Company: Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Phone: +33 44 284 5600
E-mail: info@sartorius-stedim.com
Internet: www.sartorius-stedim.com
ISIN: FR0013154002
Euronext Ticker: DIM
AMF Category: Information relating to the liquidity contract
End of Announcement EQS News Service
676767 20-Apr-2018 CET/CEST
1: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=92e2746d75382cf995a1b8fa7a9fd078&application_id=676767&site_id=vwd&application_name=news
(END) Dow Jones Newswires
April 20, 2018 01:00 ET (05:00 GMT)
